Shares of Ingevity Corporation (NYSE:NGVT – Get Free Report) have been assigned an average recommendation of “Hold” from the five brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $80.00.
NGVT has been the subject of a number of recent research reports. Weiss Ratings upgraded Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday. Wall Street Zen lowered Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday.
Read Our Latest Stock Report on Ingevity
Insider Buying and Selling
Institutional Investors Weigh In On Ingevity
Institutional investors have recently made changes to their positions in the company. Assetmark Inc. raised its position in Ingevity by 9.6% in the 1st quarter. Assetmark Inc. now owns 1,584 shares of the company’s stock worth $113,000 after purchasing an additional 139 shares during the period. Advisory Services Network LLC boosted its position in shares of Ingevity by 4.4% during the third quarter. Advisory Services Network LLC now owns 6,947 shares of the company’s stock valued at $383,000 after buying an additional 293 shares during the period. Amundi boosted its position in shares of Ingevity by 4.8% during the third quarter. Amundi now owns 6,626 shares of the company’s stock valued at $364,000 after buying an additional 302 shares during the period. Isthmus Partners LLC grew its stake in shares of Ingevity by 0.5% during the fourth quarter. Isthmus Partners LLC now owns 72,245 shares of the company’s stock valued at $4,275,000 after buying an additional 375 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in shares of Ingevity by 85.8% during the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after buying an additional 387 shares during the last quarter. Institutional investors own 91.59% of the company’s stock.
Ingevity Stock Up 4.2%
Shares of NYSE NGVT opened at $73.16 on Friday. The company has a current ratio of 1.61, a quick ratio of 0.92 and a debt-to-equity ratio of 22.52. Ingevity has a 12-month low of $39.74 and a 12-month high of $79.29. The firm’s 50-day moving average price is $71.76 and its 200-day moving average price is $70.97. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of 49.77 and a beta of 1.16.
Ingevity (NYSE:NGVT – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, topping the consensus estimate of $1.33 by $0.41. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.The company had revenue of $314.10 million during the quarter, compared to analyst estimates of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, equities research analysts anticipate that Ingevity will post 5.05 EPS for the current fiscal year.
About Ingevity
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Featured Stories
- Five stocks we like better than Ingevity
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
